Tag: NASDAQ ABUS

Business

Arbutus Biopharma Corp (NASDAQ: ABUS) and Vaccitech PLC – ADR (NASDAQ: VACC) Ink Agreement To Treat Patients With Hepatitis B Virus Infection

Arbutus Biopharma Corp (NASDAQ: ABUS) and Vaccitech PLC – ADR (NASDAQ: VACC) have entered into a partnership to carry out a clinical trial. As part of the agreement, the companies will implement therapeutic combinations to treat patients suffering from chronic hepatitis B virus (HBV) infection (CHB). Additionally, patients who are […]

Business

The US FDA Gives Arbutus Biopharma Corporation (NASDAQ: ABUS) Authority to Advance with an Investigational New Drug Application (IND) for AB-729

About 27 million people worldwide could be suffering from chronic HBV infection, and only 4.5 million are on treatment. Today’s treatment options include nucleos and pegylated interferon regimens. Unfortunately, only about 5% or less of these patients are cured by these current treatment options, while the rest have to take […]

Business

Arbutus Biopharma Corp (NASDAQ: ABUS) Receives A Nod To Investigate New Drug, Rosen Law Firm Issues Loss Alert, Halper Sadeh LLP Initiates Investigating Companies

Arbutus Biopharma Corp (NASDAQ: ABUS) is back in the news. First, the company announced that it had received a go-ahead from the U.S. Food and Drug Administration to investigate New Drug (IND) application for AB-729 in a Phase 2a clinical trial. The Phase 2a proof-of-concept clinical trial will evaluate the […]